JBIO — Jade Biosciences Cashflow Statement
0.000.00%
- $401.86m
- $325.65m
- 41
- 14
- 85
- 44
Annual cashflow statement for Jade Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -9.61 | -23 | -51.5 | -75.5 | -69.6 |
Depreciation | |||||
Non-Cash Items | 0.777 | 2.06 | 4.57 | 8.85 | 9.32 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.974 | -6.51 | 7.75 | 9.8 | -11.2 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -7.86 | -27.4 | -39.1 | -56.8 | -71.2 |
Capital Expenditures | — | -0.181 | -0.195 | -0.142 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -113 | 7.12 | 12 | 56 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | — | -113 | 6.93 | 11.9 | 56 |
Financing Cash Flow Items | — | — | -0.371 | -0.234 | -0.307 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 8.92 | 190 | 0.396 | 46 | 25.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.06 | 49.6 | -31.8 | 1.09 | 10.3 |